Eotaxin-3 in Churg-Strauss syndrome: A clinical and immunogenetic study

Jochen Zwerina*, Christian Bach, Davide Martorana, Maria Jatzwauk, Guido Hegasy, Frank Moosig, Jan Bremer, Stefan Wieczorek, Alexander Moschen, Herbert Tilg, Thomas Neumann, Bernd M. Spriewald, Georg Schett, Augusto Vaglio

*Corresponding author for this work
37 Citations (Scopus)


Objectives. To determine the potential of eotaxin-3 as a diagnostic marker for active disease and genetic susceptibility factor for Churg-Strauss syndrome (CSS). Methods. A total of 37 patients with active, relapsed or inactive CSS, 123 healthy controls and 138 disease controls were studied. Clinical data were collected and serum levels of eotaxin-3 were determined. Ex vivo stability of eotaxin-3 in serum samples was tested. Furthermore, the association of single nucleotide polymorphisms (SNPs) in the eotaxin-3 gene with CSS was determined in 161 CSS patients and 124 healthy controls. Results. Serum eotaxin-3 was highly elevated in active CSS patients. Neither eosinophilic diseases nor other small-vessel vasculitides were associated with high serum eotaxin-3 levels. Receiver operating characteristic curve analysis determined a sensitivity and specificity of 87.5 and 98.6% at a cut-off level of 80 pg/ml. None of the tested SNPs within the eotaxin-3 gene influenced the susceptibility to develop CSS. Conclusions. Serum eotaxin-3 is a sensitive and specific marker for the diagnosis of active CSS suitable for routine clinical practice. Previously described SNPs in the eotaxin-3 gene do not predict the risk of developing CSS.

Original languageEnglish
Article numberkeq445
Issue number10
Pages (from-to)1823-1827
Number of pages5
Publication statusPublished - 01.10.2011


Dive into the research topics of 'Eotaxin-3 in Churg-Strauss syndrome: A clinical and immunogenetic study'. Together they form a unique fingerprint.

Cite this